CORONA CORONA Remedies Q3 FY26 results (Oct–Dec 2025) and concall
CORONA Remedies Limited delivered strong financial results for Q3 and 9M FY26, significantly outperforming the Indian Pharmaceutical Market. Revenue and EBITDA showed robust double-digit growth, driven by volume and new product introductions. The company maintained strong cash flow generation, is pursuing strategic brand acquisitions, and has expanded its international market access through recent GMP accreditations, with a clear focus on long-term profitable growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 14.8%, net profit down 8.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 314 | 298 | 294 | 347 | 361 +15% | 342 +15% |
| EBITDA | 67 | 69 | 54 | 70 | 78 +16% | 83 +20% |
| Net profit | 43 | 45 | 31 | 46 | 52 +21% | 41 −9% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
